After helping build AlphaFold, a 34-year-old first-time CEO launches his own AI biotech with $50M

Andrew Dunn

Senior Biopharma Correspondent

Simon Kohl turned an internship at Google DeepMind into a key role in building AlphaFold2, the Nobel Prize-winning AI model that predicts the structure of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

After helping build AlphaFold, a 34-year-old first-time CEO launches his own AI biotech with $50M

Andrew Dunn

Senior Biopharma Correspondent

Sign up to read this article for free.

Sanofi faces $250M charge after J&J-partnered vaccine flunks late-stage test

Newleos, a new biotech with $93.5M, repurposes Roche's experimental CNS drugs

Hunger-suppressing biotech Aardvark raises $94M in IPO

AnaptysBio gets a mid-stage win for PD-1 drug in rheumatoid arthritis

NIH’s funding cut plan poses challenges for researchers despite court halt

Reducing risk in drug development: The importance of validated MRD testing in lymphoid cancers

Af­ter help­ing build Al­phaFold, a 34-year-old first-time CEO launch­es his own AI biotech with $50M

Andrew Dunn

Senior Biopharma Correspondent

Sign up to read this article for free.

Sanofi faces $250M charge af­ter J&J-part­nered vac­cine flunks late-stage test

Newleos, a new biotech with $93.5M, re­pur­pos­es Roche's ex­per­i­men­tal CNS drugs

Hunger-sup­press­ing biotech Aard­vark rais­es $94M in IPO

Anap­tys­Bio gets a mid-stage win for PD-1 drug in rheuma­toid arthri­tis

NIH’s fund­ing cut plan pos­es chal­lenges for re­searchers de­spite court halt

Re­duc­ing risk in drug de­vel­op­ment: The im­por­tance of val­i­dat­ed MRD test­ing in lym­phoid can­cers

After helping build AlphaFold, a 34-year-old first-time CEO launches his own AI biotech with $50M

Sanofi faces $250M charge after J&J-partnered vaccine flunks late-stage test

Newleos, a new biotech with $93.5M, repurposes Roche's experimental CNS drugs

Hunger-suppressing biotech Aardvark raises $94M in IPO

AnaptysBio gets a mid-stage win for PD-1 drug in rheumatoid arthritis

NIH’s funding cut plan poses challenges for researchers despite court halt

Reducing risk in drug development: The importance of validated MRD testing in lymphoid cancers